4-Bromo-2,6-dimethylaniline | CAS:24596-19-8

We serve 4-Bromo-2,6-dimethylaniline CAS:24596-19-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-2,6-dimethylaniline

Chemical Name:4-Bromo-2,6-dimethylaniline
CAS.NO:24596-19-8
Synonyms:4-Bromo-2,6-dimethylaniline
4-amino-3,5-dimethylbromobenzene
4-Bromo-2,6-dimethyl-phenylamine
Benzenamine,4-bromo-2,6-dimethyl
2-Amino-5-bromo-m-xylene
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 258.8±35.0 °C at 760 mmHg
Melting Point 48-51 °C(lit.)
Molecular Formula C8H10BrN
Molecular Weight 200.076
Flash Point 110.3±25.9 °C
 
Specification:
Appearance:Brown crystal
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Rilpivirine(CAS:500287-72-9).



Contact us for information like 4-Bromo-2,6-dimethylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Amino-5-bromo-m-xylene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-2,6-dimethylaniline Use and application,4-amino-3,5-dimethylbromobenzene technical grade,usp/ep/jp grade.


Related News: Since first being reported in the city of Wuhan, where it is believed to have originated at a seafood market, the virus has not provoked unusual symptoms in people who have been diagnosed.ethyl 4-methoxy-3-oxobutanoate manufacturer When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.2-Ethylaniline supplier It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation.N-BOC-4-Hydroxypiperidine vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of “predictable” clinical value for life-threatening diseases for which effective treatment is not immediately available.